Literature DB >> 9864173

ETV6-AML1 translocation breakpoints cluster near a purine/pyrimidine repeat region in the ETV6 gene.

S P Thandla1, J E Ploski, S Z Raza-Egilmez, P P Chhalliyil, A W Block, P J de Jong, P D Aplan.   

Abstract

The t(12;21)(p13;q22) translocation, fusing the ETV6 and AML1 genes, is the most frequent chromosomal translocation associated with pediatric B-cell precursor acute lymphoblastic leukemia. Although the genomic organization of the ETV6 gene and a breakpoint cluster region (bcr) in ETV6 intron 5 has been described, mapping of AML1 breakpoints has been hampered because of the large, hitherto unknown size of AML1 intron 1. Here, we report the mapping of the AML1 gene between exons 1 and 3, cloning of ETV6-AML1 breakpoints from different patients, and localization of the AML1 breakpoints within AML1 intron 1. In contrast to the tightly clustered ETV6 breakpoints, the AML1 breakpoints were found to be dispersed throughout AML1 intron 1. Although nucleotide sequence analysis of the breakpoint junctions showed several 5/7 matches for the V(D)J consensus heptamer recognition sequence, these matches were present only on the ETV6 alleles and not on the AML1 alleles, making it unlikely that the translocations were mediated by a simple V(D)J recombination mistake. Interestingly, several breakpoints as well as a stable insertion polymorphism mapped close to a polymorphic, alternating purine-pyrimidine tract in the ETV6 gene, suggesting that this region may be prone to DNA recombination events such as insertions or translocations. Finally, the presence of an insertional polymorphism within the ETV6 bcr must be recognized to avoid incorrect genotype designation based on Southern blot analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9864173

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Searching for non-B DNA-forming motifs using nBMST (non-B DNA motif search tool).

Authors:  R Z Cer; K H Bruce; D E Donohue; N A Temiz; U S Mudunuri; M Yi; N Volfovsky; A Bacolla; B T Luke; J R Collins; R M Stephens
Journal:  Curr Protoc Hum Genet       Date:  2012-04

Review 2.  Causes of oncogenic chromosomal translocation.

Authors:  Peter D Aplan
Journal:  Trends Genet       Date:  2005-10-28       Impact factor: 11.639

3.  Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally.

Authors:  Joseph L Wiemels; Jerry Hofmann; Michelle Kang; Rebecca Selzer; Roland Green; Mi Zhou; Sheng Zhong; Luoping Zhang; Martyn T Smith; Carmen Marsit; Mignon Loh; Patricia Buffler; Ru-Fang Yeh
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

4.  Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia.

Authors:  Johanna M Kralik; Wolfgang Kranewitter; Hans Boesmueller; Renate Marschon; Gertraud Tschurtschenthaler; Holger Rumpold; Kurt Wiesinger; Martin Erdel; Andreas L Petzer; Gerald Webersinke
Journal:  Diagn Pathol       Date:  2011-03-15       Impact factor: 2.644

5.  The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.

Authors:  Esmé Waanders; Blanca Scheijen; Laurens T van der Meer; Simon V van Reijmersdal; Liesbeth van Emst; Yvet Kroeze; Edwin Sonneveld; Peter M Hoogerbrugge; Ad Geurts van Kessel; Frank N van Leeuwen; Roland P Kuiper
Journal:  PLoS Genet       Date:  2012-02-16       Impact factor: 5.917

6.  Genomic inverse PCR for exploration of ligated breakpoints (GIPFEL), a new method to detect translocations in leukemia.

Authors:  Elisa Fueller; Daniel Schaefer; Ute Fischer; Pina F I Krell; Martin Stanulla; Arndt Borkhardt; Robert K Slany
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

Review 7.  RUNX1: A Regulator of NF-kB Signaling in Pulmonary Diseases.

Authors:  Xiaoju Tang; Ling Sun; Gang Wang; Bojiang Chen; Fengming Luo
Journal:  Curr Protein Pept Sci       Date:  2018       Impact factor: 3.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.